Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lr-103

    ACTIVE PHARMA INGREDIENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Lr-103, 156316-85-7, 2900i92z36, (24s)-1alpha,24-dihydroxyvitamin d2 / (24s)-1alpha,24-dihydroxyergocalciferol, (5z,7e,22e)-(1s,3r,24s)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24-triol, Unii-2900i92z36
    Molecular Formula
    C28H44O3
    Molecular Weight
    428.6  g/mol
    InChI Key
    ODZFJAXAEXQSKL-WRJREGAQSA-N
    FDA UNII
    2900I92Z36
    LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
    2.1.2 InChI
    InChI=1S/C28H44O3/c1-18(2)28(6,31)15-13-19(3)24-11-12-25-21(8-7-14-27(24,25)5)9-10-22-16-23(29)17-26(30)20(22)4/h9-10,13,15,18-19,23-26,29-31H,4,7-8,11-12,14,16-17H2,1-3,5-6H3/b15-13+,21-9+,22-10-/t19-,23-,24-,25+,26+,27-,28-/m1/s1
    2.1.3 InChI Key
    ODZFJAXAEXQSKL-WRJREGAQSA-N
    2.1.4 Canonical SMILES
    CC(C)C(C)(C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O
    2.1.5 Isomeric SMILES
    C[C@H](/C=C/[C@](C)(C(C)C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C
    2.2 Other Identifiers
    2.2.1 UNII
    2900I92Z36
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1,24(s)-dihydroxyvitamin D2

    2. 1,24-dihydroxyvitamin D2

    3. 1alpha,24(s)(oh)2d2

    4. 1alpha,24(s)-dihydroxyvitamin D2

    5. Lr-103

    2.3.2 Depositor-Supplied Synonyms

    1. Lr-103

    2. 156316-85-7

    3. 2900i92z36

    4. (24s)-1alpha,24-dihydroxyvitamin D2 / (24s)-1alpha,24-dihydroxyergocalciferol

    5. (5z,7e,22e)-(1s,3r,24s)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24-triol

    6. Unii-2900i92z36

    7. Lmst03010062

    8. 1alpha,24(s)-dihydroxyergocalciferol

    9. Schembl3026089

    10. Lr 103 [who-dd]

    11. Dtxsid801015488

    12. Zinc4791507

    13. Db06117

    14. (1alpha,3beta,5z,7e,22e,24s)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol

    15. 1.alpha.,24s-dihydroxyvitamin D2

    16. 1.alpha.,24(s)-dihydroxyergocalciferol

    17. Q27254357

    18. (1.alpha.,3.beta.,5z,7e,22e,24s)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol

    19. 9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol,(1.alpha.,3.beta.,5z,7e,22e)-

    2.4 Create Date
    2006-08-30
    3 Chemical and Physical Properties
    Molecular Weight 428.6 g/mol
    Molecular Formula C28H44O3
    XLogP35.1
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count5
    Exact Mass428.32904526 g/mol
    Monoisotopic Mass428.32904526 g/mol
    Topological Polar Surface Area60.7 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity760
    Isotope Atom Count0
    Defined Atom Stereocenter Count7
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count3
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in parathyroid disorders.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    LR-103 is effective in normalizing serum calcium and PTH levels without causing hypercalcemia. Importantly, LR-103 also normalized bone abnormalities consequent to SHPT and active vitamin D deficiency.